-The Times of India NEW DELHI: The drug price regulator has mandated companies to seek its approval for every new medicine, including combinations of existing ones, to ensure that consumers are not overcharged. According to the National Pharmaceutical Pricing Authority (NPPA) all innovative launches like new combinations of price-controlled medicines as well as those with changed strengths and dosages will be treated as 'new medicines'. The move is aimed at spanning the...

-Down to Earth Health experts blame Centre's over-emphasis on women's sterilisation for the Chhattisgarh tragedy THERE WAS nothing right about the sterilisation camp held on November 8 in Chhattisgarh's Takhatpur block of Bilaspur district. An overambitious government doctor-with unsterilised equipment and virtually no manpower-set out to conduct laparoscopic tubectomy on 83 women in an abandoned private hospital. The mass sterilisation led to the death of 13 women and left others critically ill. They were...

-IPS News Dr. Babatunde Osotimehin is the Executive Director of UNFPA, the United Nations Population Fund UNITED NATIONS: The tragic deaths and injuries of women following sterilisation in the Indian state of Chhattisgarh have sparked global media coverage and public concern and outrage. Now we must ensure that such a tragedy never occurs again. The women underwent surgery went with the best intentions - hoping they were doing the right thing for themselves and...

-The Times of India NEW DELHI: India runs the risk of a severe shortage of medicines because of its over dependence on China for sourcing raw material for drugs, national security adviser (NSA) Ajit Doval has warned, TOI has learnt. According to the NSA, India should take immediate concrete steps to create adequate infrastructure to become self-sufficient for manufacturing medicines which are essential in nature. "The national security adviser had highlighted concerns related...

-Business Standard Indian and other generic drug firms face prospect of US legislature debating compensation for undue price rises Indian generic drug makers might, if a proposed US law comes about, need to pay a rebate to the federal Medicaid programme there when prices of their medications outpace inflation. A Bill is to be introduced in the US Senate by a member, aimed to cushion the impact on taxpayers in this manner...